{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '7.2.8.', 'Future Biomedical Research', 'The biomarker samples unused for study-related research, as well as unused PK and ADA samples,', 'will be stored for up to 15 years after the final date of the database lock. The unused samples may', 'be utilized for future biomedical research of cervical cancer and other diseases. No additional', 'samples will be collected for future biomedical research. After 15 years, any residual samples will', 'be destroyed.', '7.2.8.1. Genomics Sub-study - Optional', 'Patients who agree to participate in the genomics sub-study will be required to sign a separate', 'genomics sub-study ICF before collection of the samples. Patients are not required to participate', 'in the genomics sub-study in order to enroll in the primary study. Samples for DNA extraction', 'should be collected on cycle 1 day 1 (baseline/predose) but may be collected at any study visit.', 'The DNA samples for the genomics sub-study will be double-coded as defined by the International', 'Council for Harmonisation (ICH) guideline E15. Sub-study samples will be stored for up to', '15 years after the final date of the database lock and may be used for research purposes. The', 'purpose of the genomic analyses is to identify genomic associations with clinical or biomarker', 'response, other clinical outcome measures, and possible AEs. In addition, associations between', 'genomic variants and prognosis or progression of other diseases may also be studied. These data', 'may be used or combined with data collected from other studies to identify and validate genomic', 'markers related to the study treatment or other diseases. Analyses may include sequence', 'determination or single nucleotide polymorphism studies of candidate genes and surrounding', 'genomic regions. Other methods, including whole-exome sequencing, whole-genome sequencing,', 'and DNA copy number, may also be performed. The list of methods may be expanded to include', 'novel methodology that may be developed during the course of this study or sample storage period.', '8.', 'STUDY TREATMENTS', '8.1.', 'Investigational and Reference Treatments', 'The term \"investigational product\" (study drug) includes the experimental treatment cemiplimab', '(REGN2810) and the IC chemotherapy treatments. In this protocol, the investigational products', '(study drugs) are:', 'Cemiplimab (experimental group)', 'Antifolate: Pemetrexed (an IC option in the control group)', 'Topoisomerase inhibitor: Topotecan or irinotecan (IC options in the control group)', 'Nucleoside analogue: Gemcitabine (an IC option in the control group)', 'Vinca alkaloid: Vinorelbine (an IC option in the control group)', 'The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed', 'as IC options. Other agents in these classes are not permitted in this study. Preference should be', 'given to regimens that are allowed by local regulations.', 'Regeneron Pharmaceuticals, Inc.', 'Page 66 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', \"Regeneron will provide cemiplimab. Investigator's choice chemotherapy (pemetrexed, topotecan,\", 'irinotecan, gemcitabine, and vinorelbine) should be procured by investigative sites as local', 'commercial product, where allowed by local regulations. In countries in which local regulations', 'do not allow IC chemotherapy to be procured as local commercial product for the study, Regeneron', 'may provide the chemotherapy to the study sites. The sites will also procure any supplies needed', 'for administration of investigational product, including IV bags, diluents, lines, and filters.', 'Investigational product will be stored in a secure area according to local regulations.', '8.1.1.', 'Experimental Group Treatment (Cemiplimab)', 'Open-label cemiplimab will be supplied as a liquid in sterile, single-use vials. Each vial will', 'contain cemiplimab at a concentration of 50 mg/mL. Instructions on dose preparation are provided', 'in the pharmacy manual.', 'Open-label cemiplimab will be administered in an outpatient setting as a 30-minute IV infusion.', \"Each patient's dose will be administered as a flat dose of 350 mg Q3W.\", 'A pharmacist or other qualified individual will be identified at each site to prepare cemiplimab for', 'administration. The prepared infusion bag should be kept no more than 6 hours at room', 'temperature, or no more than 24 hours at 2\u00b0C to 8\u00b0C. Detailed preparation and administration', 'instructions will be provided to the sites in the pharmacy manual.', '8.1.2.', \"Control Group Treatments (Investigator's Choice)\", \"Patients assigned to the control arm will receive one of the Investigator's Choice chemotherapy\", 'options, as follows:', 'Antifolate: Pemetrexed, 500 mg/m\u00b2 IV every 21 days, for up to 96 weeks of treatment.', 'Vitamin B12 and folate support will be provided according to standard of care with', 'pemetrexed (Lorusso 2010)', 'Topoisomerase 1 inhibitor: Topotecan, 1 mg/m\u00b2 daily IV for 5 days, every 21 days, for', 'up to 96 weeks of treatment (Bookman 2000); or irinotecan 100 mg/m\u00b2 IV weekly X 4,', \"followed by 10 to 14 days' rest, for up to 96 weeks of treatment (Look 1998)\", '(Takeuchi 1991). For patients enrolling in Japan, there will be at least 14 days of rest', 'before subsequent irinotecan administration', 'NOTE: For patients without significant toxicity during the first 21-day course of', 'topotecan, subsequent courses may be increased to 1.25 mg/m\u00b2 x 5 days, every 21 days.', 'NOTE: For patients without significant toxicity during the first 42-day course of', 'irinotecan, subsequent courses may be increased to 125 mg/m\u00b2 IV weekly x 4, followed', 'by 2 weeks rest', 'Nucleoside analogue: Gemcitabine, 1000 mg/m\u00b2 IV on days 1 and 8 and every 21 days,', 'for up to 96 weeks of treatment (Mutch 2007) (Schilder 2005)', 'Vinca alkaloid: Vinorelbine 30 mg/m\u00b2 IV on days 1 and 8 and every 21 days, for up to', '96 weeks of treatment (Muggia 2004) (Muggia 2005)', 'The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed', 'as IC options. Other agents in these classes are not permitted in this study.', 'Regeneron Pharmaceuticals, Inc.', 'Page 67 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}